Fig. 4From: A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary diseaseForest plot of treatment ratio (90% CI) by subgroup (mITT population). Values <1 represent a reduction of AECOPD rate relative to placebo. Analysed using Poisson regression with Pearson correction, adjusting for treatment, background therapy and history of previous exacerbations AECOPD acute exacerbations of chronic obstructive pulmonary disease, BMI body mass index, CI confidence interval, CRP C-reactive protein, CV cardiovascular, FEV 1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, mITT modified intention-to-treat, MMRC Modified Medical Research Council dyspnoea scaleBack to article page